Fundraising Fox

Massive Bio

New York, US · Founded 2015 · Delaware corporation · 4 known investors

Massive Bio operates an AI-based platform that matches cancer patients with oncology clinical trials and provides concierge support throughout the trial process. It serves patients across the U.S., Canada, Latin America, and Europe, and works with pharma and CRO customers, patient advocacy organizations, and the National Cancer Institute's network of cancer centers.

AI & Machine LearningBiotechDigital HealthHealthtech

Founders & leadership

Massive Bio was founded in 2015 by Selin Kurnaz and Arturo Loaiza-Bonilla.

SKSelin Kurnaz
Selin Kurnazin𝕏Co-founder
ALArturo Loaiza-Bonilla
Arturo Loaiza-Bonillain𝕏Co-Founder & Chief Medical  AI Officer (CMAIO)

Investors · 4

500 Emerging EuropeAmsterdam
500 GlobalSan Francisco · $150K
Revo CapitalIstanbul · $250K – $5M
e2vcreported

Reported raises · per SEC filings

Form D private placements

$2.5M disclosed across 1 round · 2019

▶$2.5MraisedMay 2019 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Selin KurnazExecutive Officer
  • Arturo Loaiza-BonillaDirector
Offering amount
$5.5M
Amount sold
$2.5M
Minimum investment
$500K
First sale
Apr 2019
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
Osmosis27914 shared keywordsOsmosis is a US health education platform of short-form medical videos and learning tools, acquired by Elsevier.
Medscape27407 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.

Companies competing with Massive Bio for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2020$399.6K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Massive Bio Makes Inaugural Strategic Investment in Rivvi to Build an End-to-End AI Engagement Infrastructure for Healthcare - AOLaol.com · Aug 2026Massive Bio Raises $9 Million To Scale Growth and Fuel Global Expansion of AI-Enabled Oncology Clinical Trial Platformmassivebio.com · Jun 2022Massive Bio Raises $2.6 Million for Oncology Clinical Trial Platform - Mercom Capital Groupmercomcapital.com · Nov 2020Massive Bio Secures Additional $2.6 Million Financing Round Led by Revo Capital and Tops its Total Raise to $6.6 Million - Boston Real Estate Timesbostonrealestatetimes.com · Nov 2020

Frequently asked questions

What does Massive Bio do?
Massive Bio operates an AI-based platform that matches cancer patients with oncology clinical trials and provides concierge support throughout the trial process. It serves patients across the U.S., Canada, Latin America, and Europe, and works with pharma and CRO customers, patient advocacy organizations, and the National Cancer Institute's network of cancer centers.
Who founded Massive Bio?
Massive Bio was founded by Selin Kurnaz, Arturo Loaiza-Bonilla in 2015.
Who are Massive Bio's investors?
Massive Bio's investors include 500 Emerging Europe, 500 Global, Revo Capital, e2vc.
How much funding has Massive Bio raised?
Massive Bio has disclosed $2.5M raised across 1 round.
Where is Massive Bio headquartered?
Massive Bio is headquartered in New York, US.